BioSure Ltd has today been honoured with a Queen’s Award for Enterprise: Innovation 2021

Essex based BioSure, is one of the 205 organisations nationally recognised with this globally renowned and prestigious Queen’s Award for Enterprise, presented for Innovation. BioSure has been recognised for its excellence in Innovation for their BioSURE HIV Self Test, which launched in 2015 as the world’s first approved blood-based HIV self-test. The test requires only a fraction of a drop of blood and gives incredibly accurate results in just 15 minutes

Securing a coveted Queen’s Award is not easy. The Innovation category is aimed at organisations who are innovative in their practices as a whole and in addition to their award-winning HIV self-test, BioSure are actively delivering their company mission of being part of the solution to deliver the end of the HIV/AIDS epidemic, by changing the conversation in the way people think about HIV and helping them to take control and feel empowered to know their own HIV status, on their own terms.

Since the beginning of the global pandemic, BioSure has collaborated with other UK diagnostic manufacturers and have also launched a range of COVID-19 tests, including their BioSURE COVID-19 IgG Antibody Self Test that allows people to know if they have developed neutralising antibodies to the virus.

Brigette Bard CEO of BioSure says “It is a true honour to be recognised for the prestigious Queen’s Award for Enterprise, especially following the challenges of the past year.

As a company we are passionate about self-testing and believe it will change the dynamic of healthcare, taking the strain from overwhelmed healthcare services. Self-testing provides people with a choice, which is critical for getting more people to test, plus it offers an incredibly cost-effective solution.

Our success has been built on our consumer responsive approach – everything we do is designed and refined with the unique needs of our customers in mind”.

Applications for the Queen’s Awards for Enterprise 2022 open on the 1st of May 2021. For more information, visit

For more information on BioSure Ltd or interviews with Brigette Bard CEO of BioSure, please contact Suzanne Hobday or 0845 2220012